United Kingdom & European Union — European Medicines Agency
4 shared events · Importance 7 · Last updated Jun 25, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Regulatory
United Kingdom: The United Kingdom is the first country where INmune Bio Inc. has received a key regulatory approval for Ebstrocel, paving the way for a Marketing Authorization Application (MAA) and potential market access for patients with Recessive Dystrophic Epidermolysis Bullosa (RDEB).
European Union — European Medicines Agency: The European Union — European Medicines Agency (EMA) is mentioned as a target for a Marketing Authorization Application (MAA) in 2026 for INmune Bio Inc.'s CORDStrom platform, indicating future regulatory efforts in the European Union.
Jun 25, 2026 · 6 articles
Business
United Kingdom: The United Kingdom>>> is one of the regions where SERB Pharmaceuticals>>> will acquire rights to Imlifidase>>>.
European Union — European Medicines Agency: The European Union — European Medicines Agency>>> is involved in the approval process for Imlifidase>>>, with a payment contingent on its filing acceptance.
May 19, 2026 · 7 articles
NEWSDESK
Explore this relationship live
Track how United Kingdom and European Union — European Medicines Agency interact across events, view sentiment trends, and discover connected entities.
Open Dashboard